Euroespes, S.A., a medical center, provides medical services for the prevention, diagnosis, and treatment of central nervous system disorders and other diseases in Spain and internationally.
The last earnings update was 173 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Euroespes. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Euroespes's earnings available for a low price, and how does
this compare to other companies in the same industry?
Euroespes's earnings are expected to grow significantly at over 20% yearly.
Unable to determine if Euroespes is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Euroespes's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
What Kind Of Share Price Volatility Should You Expect For Euroespes, S.A. (BME:EEP)?
Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. … Beta is a widely used metric to measure a stock's exposure to market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market.
Does Euroespes SA's (BME:EEP) P/E Ratio Signal A Buying Opportunity?
This article is written for those who want to get better at using price to earnings ratios (P/E ratios). … To keep it practical, we'll show how Euroespes SA's (BME:EEP) P/E ratio could help you assess the value on offer. … Price to Earnings Ratio = Share Price ÷ Earnings per Share (EPS)
Will EuroEspes SA. (BME:EEP) Continue To Underperform Its Industry?
Return on Equity = Net Profit ÷ Shareholders Equity ROE is measured against cost of equity in order to determine the efficiency of EuroEspes’s equity capital deployed. … This is called the Dupont Formula: Dupont Formula ROE = profit margin × asset turnover × financial leverage ROE = (annual net profit ÷ sales) × (sales ÷ assets) × (assets ÷ shareholders’ equity) ROE = annual net profit ÷ shareholders’ equity BME:EEP Last Perf May 22nd 18 Essentially, profit margin shows how much money the company makes after paying for all its expenses. … And finally, financial leverage is simply how much of assets are funded by equity, which exhibits how sustainable the company’s capital structure is.
Should You Have EuroEspes SA.'s (BME:EEP) In Your Portfolio?
Generally, an investor should consider two types of risk that impact the market value of EEP. … A popular measure of market risk for a stock is its beta, and the market as a whole represents a beta value of one. … Based on this beta value, EEP appears to be a stock that an investor with a high-beta portfolio would look for to reduce risk exposure to the market.
Is EuroEspes SA. (BME:EEP) A Financially Sound Company?
EEP has built up its total debt levels in the last twelve months, from €2.91M to €3.82M , which is made up of current and long term debt. … Additionally, EEP has produced €451.25K in operating cash flow during the same period of time, leading to an operating cash to total debt ratio of 11.82%, indicating that EEP’s operating cash is not sufficient to cover its debt. … For EEP, the ratio of 3.08x suggests that interest is appropriately covered, which means that lenders may be inclined to lend more money to the company, as it is seen as safe in terms of payback.Next Steps: With a high level of debt on its balance sheet, EEP could still be in a financially strong position if its cash flow also stacked up.
Does EuroEspes SA.'s (BME:EEP) Past Performance Indicate A Stronger Future?
In this article, I will take a look at EuroEspes SA.'s (BME:EEP) most recent earnings update (30 June 2017) and compare these latest figures against its performance over the past few years, along with how the rest of EEP's industry performed. … View our latest analysis for EuroEspes Commentary On EEP's Past Performance For the purpose of this commentary, I like to use data from the most recent 12 months, which either annualizes the most recent 6-month earnings update, or in some cases, the most recent annual report is already the latest available financial data. … Given that these values may be fairly nearsighted, I’ve estimated an annualized five-year value for EuroEspes's net income, which stands at €279.48K This shows that, on average, EuroEspes has been able to steadily improve its earnings over the past couple of years as well.
Euroespes, S.A., a medical center, provides medical services for the prevention, diagnosis, and treatment of central nervous system disorders and other diseases in Spain and internationally. The company offers personalized and genomic medicine services for predictive, diagnostic, and therapeutic purposes. It also provides medical services, such as genomics, digital diagnosis, diagnostic imaging, neuro-psychology, neuro-ophthalmology, nursing, epigenetics, and clinical analysis services, as well as medical research services. In addition, the company offers pharmacogenetic cards; human identification cards based on genetic footprint; and a range of nutraceuticals. Euroespes, S.A. was founded in 1991 and is based in A Coruña, Spain.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.